Novartis AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public, Private
- Established
- 1996-01-01
- Employees
- 76K
- Market Cap
- $242.6B
- Introduction
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
To Demonstrate Non-inferiority of Combination of 5 mg Amlodipine/ 80 mg Valsartan to 160 mg Valsartan Alone
- Conditions
- HypertensionHigh Blood Pressure
- Interventions
- First Posted Date
- 2010-02-17
- Last Posted Date
- 2011-10-19
- Lead Sponsor
- Novartis
- Target Recruit Count
- 60
- Registration Number
- NCT01070043
To Compare the Effect of a Subcutaneous Canakinumab Administration to Placebo in Patients With Impaired Glucose Tolerance or Patients With Type 2 Diabetes With Differing Baseline Diabetes Therapies
- Conditions
- Type 2 Diabetes MellitusImpaired Glucose Tolerance
- Interventions
- First Posted Date
- 2010-02-15
- Last Posted Date
- 2011-09-05
- Lead Sponsor
- Novartis
- Target Recruit Count
- 246
- Registration Number
- NCT01068860
- Locations
- 🇺🇸
National Research Institute, Los Angeles, California, United States
🇺🇸Crest Clinical Trials, Santa Ana, California, United States
🇺🇸Encompass Clinical Research, Spring Valley, California, United States
Comparison of Efficacy of Indacaterol Versus Placebo Over 12 Weeks
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- First Posted Date
- 2010-02-15
- Last Posted Date
- 2011-08-19
- Lead Sponsor
- Novartis
- Target Recruit Count
- 318
- Registration Number
- NCT01068600
- Locations
- 🇺🇸
Novartis Investigative Site, Richmond, Virginia, United States
🇺🇸Novartis Investigator Site, McKinney, Texas, United States
🇺🇸Novartis Investigative site, Greenville, South Carolina, United States
A Clinical Study With Aliskiren Alone or in Combination Therapy With Diuretic Hctz in Venezuelan Hypertensive Patients.
- First Posted Date
- 2010-01-26
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 253
- Registration Number
- NCT01056731
- Locations
- 🇻🇪
Investigative Site, Maracaibo Estado Zulia, Venezuela
A Study to Assess the Persistence of a GBS Antibody in Women Previously Immunized With a GBS Vaccine
- Conditions
- Group B Streptococcus (GBS) Disease
- Interventions
- Biological: Group B streptococcus (GBS) vaccine
- First Posted Date
- 2010-01-21
- Last Posted Date
- 2017-06-14
- Lead Sponsor
- Novartis
- Target Recruit Count
- 50
- Registration Number
- NCT01052935
- Locations
- 🇨🇭
Institute for Pharmacokinetic and Analytical Studies, Via Mastri, 36, CH - 6853 Ligornetto, Switzerland
Efficacy of Aliskiren Compared to Ramipril in the Treatment of Moderate Systolic Hypertensive Patients
- Conditions
- Essential Hypertension
- Interventions
- First Posted Date
- 2010-01-05
- Last Posted Date
- 2012-04-03
- Lead Sponsor
- Novartis
- Target Recruit Count
- 506
- Registration Number
- NCT01042392
- Locations
- 🇫🇷
Novartis Investigative Site, Witry-Les-Reims, France
🇫🇷Novartis Investigator Site, Marsilly, France
🇫🇷Investigative Site, Toulon, France
Proof of Concept Study Efficacy of an Antacid/Lansoprazole Combination for Relief of Heartburn
- Conditions
- Heartburn
- Interventions
- First Posted Date
- 2009-12-23
- Last Posted Date
- 2011-03-28
- Lead Sponsor
- Novartis
- Target Recruit Count
- 120
- Registration Number
- NCT01037452
Ranibizumab for the Treatment of Choroidal Neovascularisation (CNV) Secondary to Pathological Myopia (PM): an Individualized Regimen
- First Posted Date
- 2009-12-23
- Last Posted Date
- 2016-04-19
- Lead Sponsor
- Novartis
- Target Recruit Count
- 65
- Registration Number
- NCT01037348
- Locations
- 🇬🇧
Novartis Investigative Site, York, United Kingdom
🇬🇧Novartis Investigational Site, City of London, United Kingdom
Safety of Phenylephrine Hydrochloride, Acetaminophen, Dimethindene Maleate Compared to Phenylephrine Hydrochloride Alone in Healthy Volunteers
- Conditions
- Heart RateBlood PressureArrhythmias
- Interventions
- First Posted Date
- 2009-12-07
- Last Posted Date
- 2016-03-03
- Lead Sponsor
- Novartis
- Registration Number
- NCT01026961
- Locations
- 🇧🇷
Scentryphar Pesquisa Clinica Ltda., Campinas, São Paulo, Brazil
Once-a-day Regimen With Everolimus, Low Dose Cyclosporine and Steroids in Comparison With Steroid Withdrawal or Twice a Day Regimen With Everolimus, Low Dose Cyclosporine and Steroids.
- Conditions
- de Novo Kidney Transplant RecipientsRenal Transplantation
- Interventions
- First Posted Date
- 2009-12-02
- Last Posted Date
- 2016-07-19
- Lead Sponsor
- Novartis
- Target Recruit Count
- 330
- Registration Number
- NCT01023815
- Locations
- 🇮🇹
Novartis Investigative Site, Vicenza, Italy
🇮🇹Novarits Investigative Site, Pisa, Italy
🇮🇹Novartis InvestigativeSite, Udine, Italy